SECsense Logo

Hepion Pharmaceuticals, Inc. 10-K/A Amendment No. 2: Key Corrections & Compliance Insights

$HEPA
Form 10-K/A
Filed on: 2025-01-13
Source
Hepion Pharmaceuticals, Inc. 10-K/A Amendment No. 2: Key Corrections & Compliance Insights

Here are the key insights extracted from the provided section of the financial report for Hepion Pharmaceuticals, Inc.:

  1. Filing Information:
  • This document is an Amendment No. 2 to Form 10-K/A for the fiscal year ending December 31, 2023.
  • It was filed with the SEC to correct errors in the previously filed Amendment No. 1, specifically in Part III, Item 11 (Executive Compensation) and Item 12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters).
  1. Company Identification:
  • Company Name: Hepion Pharmaceuticals, Inc.
  • CIK Number: 0001583771
  • State of Incorporation: Delaware (DE)
  • Employer Identification Number (EIN): 46-2783806
  • Address: 399 Thornall Street, First Floor, Edison, NJ 08837
  • Phone: (732) 902-4000
  1. Common Stock Information:
  • Par Value: $0.0001 per share
  • Total Shares Outstanding: 40,300,000 shares as of the latest filing date.
  • Common Stock is the only class mentioned.
  1. Filing Status:
  • The company is classified as a "Non-accelerated Filer," indicating it meets specific criteria for filing deadlines and requirements set by the SEC.
  1. Accounting Firm:
  • The report mentions Grassi & Co., CPAs, P.C., located in Jericho, New York, which is presumably the company's auditor.
  1. Sarbanes-Oxley Compliance:
  • The amendment includes the certifications required under Section 302 of the Sarbanes-Oxley Act of 2002, reinforcing compliance with regulatory requirements.
  1. Forward-Looking Statements:
  • The amendment clarifies that forward-looking statements made in the previously submitted Amended Form 10-K have not been updated to reflect events or facts that became known after its filing. Stakeholders should consider these statements in their historical context.
  1. No Additional Changes:
  • Aside from the corrections specified, no other changes have been made to the previously filed Amended Form 10-K.

This summary provides an overview of the critical aspects of the filing, highlighting compliance, corrections made, and essential company information.